Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
3.120
-0.120 (-3.70%)
At close: Mar 9, 2026, 4:00 PM EDT
3.080
-0.040 (-1.29%)
After-hours: Mar 9, 2026, 5:13 PM EDT
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
10.61M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIMNN News
- 4 weeks ago - IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY - GlobeNewsWire
- 2 months ago - IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 2 months ago - IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 - GlobeNewsWire
- 4 months ago - Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript - Seeking Alpha
- 4 months ago - IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer - GlobeNewsWire
- 4 months ago - IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer - GlobeNewsWire